Repligen Corp (NAS:RGEN)
$ 169.64 -2.14 (-1.25%) Market Cap: 9.49 Bil Enterprise Value: 9.56 Bil PE Ratio: 679.32 PB Ratio: 4.81 GF Score: 93/100

Repligen Corp at Barclays Global Healthcare Conference Transcript

Mar 11, 2020 / 07:50PM GMT
Release Date Price: $91 (-5.07%)
Jack Meehan
Barclays Bank PLC, Research Division - VP & Senior Research Analyst

Thank you and good afternoon. This is Jack Meehan with the Barclays Life Science Tools and Diagnostics team. Pleased to be joined now with Repligen and glad they are joining us in this virtual format with CFO, Jon Snodgres, as well as Head of Investor Relations, Sondra Newman. Thank you, again, and Jon, Sondra, would you like to make any introductory comments?

Jon K. Snodgres
Repligen Corporation - CFO & Secretary

Yes, we sure would. Thank you, Jack, and pleasure to be here, and thank you guys for continuing the conference virtually.

So quickly, I'll give you an overview of Repligen. For those of you who may not know this -- know us, Repligen is a leading innovator and supplier into the fast-growing bioprocessing market, where we supply products to large biopharmaceutical, CDMO, gene and cell therapy, and other types of customers on a worldwide basis. The overall bioprocessing market that we look at is about $10 billion annually and is expected to grow at an 8%

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot